About Us
At UB Therapeutics, we are dedicated to advancing healthcare through the development of novel cyclic peptide therapies. Founded by a team of experienced scientists and industry professionals, our company is committed to addressing unmet medical needs and improving patient outcomes. With a focus on rigorous research and clinical excellence, we strive to bring breakthrough treatments to market.
Our
Technology
Interacting with the proteasome system in a new mode of action
UB Therapeutics specializes in the development of cyclic peptides, a promising class of therapeutics known for their stability, specificity, and efficacy. Our lead candidate, UB4a-GRR, targets multiple myeloma by inhibiting proteasome activity, a critical pathway in cancer cell survival. Through innovative design and extensive preclinical studies, we aim to deliver safer and more effective treatments for patients.
Publications
Our Team.
Our team combines science, medicine, and business expertise to achieve our mission
Dr. Dima Ghannam Shahabri
CEO
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Dr. Dima Ghannam-Shahbari,
CEO of UB Therapeutics, is a visionary leader with a decade of R&D expertise.
Holding a Ph.D. in Medical Sciences from Technion, her research in cancer biology, particularly ovarian cancer, has been widely recognized and published. Dima's extensive knowledge spans genetics, molecular biology, immunology, and advanced microscopy techniques.
As a dynamic and dedicated researcher, she has successfully led multiple projects and mentored upcoming scientists, driving UB Therapeutics toward groundbreaking achievements in cancertreatment.
Prof. Ashraf Brik
Founder
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Prof. Ashraf Brik is a world-renowned chemist at the Technion-Israel Institute of
Technology.
His groundbreaking research in chemical biology has revolutionized the
understanding of protein modification and ubiquitin signaling, paving the way for
innovative drug discovery. With over 145 publications and numerous prestigious
awards, including the Israel Chemical Society Prize of Excellence and the Advanced ERC Grant, Prof. Brik's work continues to inspire and drive advancements in the
field.
Prof. Peretz Lavie
Director
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Prof. Peretz Lavie is a distinguished figure in sleep disorder research and a former President of the Technion-Israel Institute of Technology.
With a rich history of establishing leading research centers and companies in medical equipment for sleep
testing, Prof. Lavie's expertise and leadership have significantly impacted both academic and industrial spheres.
His role as a director on behalf of the Technion brings invaluable strategic guidance and insight to UB Therapeutics, further strengthening our mission to develop groundbreaking treatments.
Sahar Saadi
Researcher
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Sahar Saadi brings a wealth of expertise in biotechnology engineering and
pharmaceutical quality control.
With a master's degree in Medical Sciences, Sahar has significant experience in cancer research, particularly in hematological cancers.
Her skills in tissue culture, molecular biology, fluorescence microscopy, and real-time qPCR make her an invaluable asset to our team, contributing to cutting-edge research and innovation in oncology.
Zohar Gindler
Director
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Zohar Gindler is a seasoned investor and entrepreneur with an impressive track
record of establishing and investing in over 50 companies.
His notable successes include Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), and Corindus (sold to Siemens for $1.1B).
Zohar's extensive experience and strategic vision play a crucial role in guiding UB Therapeutics towards impactful and successful ventures in the biotech industry.
Nizar Mishael
CFO & Director
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Nizar Mishael, co-founder of NGT Fund I, has over 15 years of experience as CFO
of start-up companies.
With hands-on financial expertise from seed investment to early and late financing rounds, Nizar excels in structuring complex investment and
business interactions.
His deep understanding of financial and accounting principles, combined with his strategic vision, ensures robust financial management and growth for UB Therapeutics.
Livnat Ben Zur
CBO
Helvetica Light is an easy-to-read font, with tall and narrow letters, that works well on almost every site.
Livnat Ben-Zur has over 20 years of executive experience in the medical device and healthcare industries, specializing in management, business development, and marketing.
She has led global product development projects and business efforts from design through commercial launch.
​
Previously, Livnat was the CEO of Corolabs and the General Manager of Regentis Biomaterials. She also served as the vice president of Business Development at Galil Medical and held leadership roles at Medinol Ltd. and Datamonitor Inc.
